Lymphoma patients get continued access to experimental drug in Long-Term safety study

NCT ID NCT05688475

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers ongoing treatment with the drug CC-122 (Avadomide) to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor long-term safety and serious side effects. Participants may also receive dexamethasone alongside CC-122.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CC-122 (Avadomide) with or without dexamethasone
What this could lead to: If successful, this could show that long-term CC-122 treatment is safe and helps control Non-Hodgkin Lymphoma over many years.
What could go wrong: This is a small, early-phase extension study with only 12 participants, so results may not apply broadly. Long-term side effects remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma follicular lymphoma non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Local Institution - 100

New York, New York, 10065, United States
Local Institution - 101

Nashville, Tennessee, 37203, United States
Local Institution - 102

Madison, Wisconsin, 53792, United States
Local Institution - 300

Bordeaux, 33076, France
Local Institution - 301

Marseille, 13273, France
Local Institution - 400

Amsterdam, 1105, Netherlands
Local Institution - 500

Koto-ku, Tokyo, 1358550, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.